GlassScriptPhysician profile
William H Evans
NPI 1477998680
$17,612.13
in general payments reported to CMS, 2019-2025
42 companies · $3,841 in 2025
The $3,841 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,376 · 2020: $1,330 · 2021: $1,736 · 2022: $1,652 · 2023: $5,951 · 2024: $1,727 · 2025: $3,841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,879 · Education: $4,596 · Travel and Lodging: $1,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,878.59 |
| Education | $4,596.37 |
| Travel and Lodging | $1,043.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,646.58 | 2023-2025 | Ion, Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $2,331.35 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,897.01 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Actelion Pharmaceuticals US, INC. | $1,416.95 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,315.59 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $840.72 | 2019-2025 | Dupixent |
| Insmed, INC. | $598.31 | 2020-2025 | Arikayce, Brinsupri |
| Takeda Pharmaceuticals U.S.A., INC. | $401.41 | 2020-2025 | Glassia, Cuvitru |
| Bayer Healthcare Pharmaceuticals INC. | $382.14 | 2019-2025 | |
| United Therapeutics Corporation | $335.88 | 2021-2025 | Tyvaso, Orenitram, Remodulin |
| Merck Sharp & Dohme LLC | $328.74 | 2023-2025 | Winrevair, Zerbaxa, Recarbrio |
| Genzyme Corporation | $249.74 | 2020-2025 | |
| Mylan Specialty L.P. | $226.25 | 2019-2023 | Yupelri |
| Electromed, INC. | $200.09 | 2021-2024 | Smartvest |
| Paratek Pharmaceuticals, INC. | $169.91 | 2020-2024 | Nuzyra |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $162.97 | 2023-2025 | Tezspire |
| Gilead Sciences, INC. | $140.66 | 2019-2025 | Veklury |
| Grifols USA, LLC | $106.78 | 2022-2025 | Prolastin-C Liquid |
| Verona Pharma, INC. | $101.30 | 2025 | Ohtuvayre |
| Sunovion Pharmaceuticals INC. | $64.62 | 2019-2020 | |
| Vapotherm INC | $54.57 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $53.26 | 2020-2021 | |
| Baxter Healthcare | $49.07 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Mallinckrodt Hospital Products INC. | $46.78 | 2022 | |
| Ethicon INC. | $46.55 | 2020-2022 | |
| Viatris Specialty LLC | $41.85 | 2025 | Yupelri |
| Portola Pharmaceuticals, LLC | $39.61 | 2019-2020 | |
| Fisher & Paykel Healthcare INC | $39.00 | 2022 | |
| Resmed Corp | $36.87 | 2022-2023 | |
| Genentech USA, INC. | $35.09 | 2019-2022 | |
| Circassia INC. | $32.94 | 2019 | |
| Livanova USA, INC. | $29.26 | 2021 | |
| Inogen, INC. | $22.57 | 2025 | |
| Pulmonx Corporation | $22.39 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Ambu INC. | $22.01 | 2025 | |
| Alexion Pharmaceuticals, INC. | $20.91 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.09 | 2019 | |
| Medtronic, INC. | $18.94 | 2021 | |
| Pfizer INC. | $16.90 | 2019 | |
| Boston Scientific Corporation | $16.49 | 2022 | |
| Abbvie INC. | $15.68 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $15.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.